Skip to main content
OpenTrials
Recruiting

NCT Number: NCT02299466

Registry for Patients Receiving Intravenous Nutrition at Home

The purpose of study is to build a Canadian HTPN Registry to collect pertinent demographic and clinical data on the HTPN population in Canada and to determine the factors affecting survival, complications and TPN-dependency. These results will help establish standards of practice and develop future multi-center studies. This will greatly benefit the HTPN patient population.

Recruiting

Interested in participating?

Request Info

Key information

Age range

18 year and older

Sex eligibility

All sexes

Study type

Observational

Primary location

Foothills Medical Centre, Calgary, Alberta, Canada

Loading trial locations.

About this study

The HTPN Registry is website based. Only users inside of Canada will be able to access the website. All data is held in Ontario, Canada and is governed by Ontario and Canadian privacy and security laws. The entry point into the registry will be through a website www.htpnregistry.ca, using a specific HTPN program password for data entry. A code and date of birth will be used to identify each patient. Patient data will be kept confidential and be entered by a member of the TPN team from each participating program. Participating programs will have access to their own database and will be able to compare their patient population to the one of the entire registry. Data entered into the registry will include: 1) Patient demography 2) Nutritional assessment 3) Medications 4) Indications for HTPN 5) Gastrointestinal anatomy following surgeries 6) HTPN regimen 7) Current blood work 8) Vascular access 9) Hospitalizations 10) Survival, 11) Liver complications 12) Metabolic bone disease 13) quality of life. In addition, information regarding each HTPN program will be captured: organization of the TPN team, number of patients under the program, diagnosis and reasons for HTPN, source of funding, geographical coverage, home care utilization, providers. Data will be entered every two years by the one or more HTPN staff monitoring the patients. The data can be entered directly into the website or case report forms can be used to collect the data from the patient charts and facilitate data input into the website.

All patients will be followed prospectively until discontinuation of TPN or death. Descriptive statistics will be performed.

For the entire HTPN population, probability of survival, chronic cholestasis, complicated home parenteral nutrition related liver disease, line infection and metabolic bone disease will be calculated using the Kaplan-Meier method. As of February 2014, 433 patients (85 from UHN) have been entered into the Canadian HTPN registry. The recruitment and data collection is expected to continue for at least 5 more years (until 2019). Participating HTPN programs are: Toronto (Toronto General Hospital, St. Michael's Hospital), Hamilton (Hamilton Health Sciences),Winnipeg (St. Boniface General Hospital), Edmonton (Capital Health/University Of Alberta), Calgary (Foothills Medical Centre), British Columbia (BC Home Parenteral Nutrition Program) and Montreal (McGill University).

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Patients with long-term administration of home total parenteral nutrition Age >18 years

Exclusion criteria

  • None

Treatment and study plan

Primary outcomes

  1. Nutritional status

    Time frame: bi-annually up to 10 years, discontinuation of HTPN or death

    Body weight, body mass index

Secondary outcomes

  1. Patient characteristics

    Time frame: baseline

    Age, sex, medical history

  2. Medications

    Time frame: bi-annually up to 10 years, discontinuation of HTPN or death

    Immunosuppressors, motility agents, antidiarrheal, sedatives, antidepressors, anticoagulants, insulin, inhibitors of acid secretion, medication to treat liver disease (eg. urso, carnitine, choline…), medication to treat metabolic bone disease (eg. iv/oral calcium, vitamin D, biphosphonate, calcitonin,… are collected from the charts

  3. Indications for HTPN

    Time frame: bi-annually up to 10 years, discontinuation of HTPN or death

    Short bowel, motility disorder, cancer, surgical complications, pancreatic disorders, other causes of malabsorption

  4. Gastrointestinal anatomy

    Time frame: bi-annually up to 10 years, discontinuation of HTPN or death

    Anatomy as described in medical records

  5. HTPN regimen

    Time frame: bi-annually up to 10 years, discontinuation of HTPN or death

    Energy, amino acids, lipids, fluid, electrolytes, vitamins, trace elements

  6. Current blood work

    Time frame: bi-annually up to 10 years, discontinuation of HTPN or death

    Complete blood count , biochemistry including liver enzymes, total protein, albumin, prealbumin, vit B12, red blood cell folate, iron studies,international normalized ratio /prothrombin time /partial thromboplastin time , cholesterol, triglycerides, trace elements;parathyroid hormone , 24-hr urine oxalate

  7. Vascular access

    Time frame: bi-annually up to 10 years, discontinuation of HTPN or death

    type of catheter, number of lumens, changes in vascular access, complications (line sepsis, occlusion)

  8. Hospitalizations

    Time frame: bi-annually up to 10 years, discontinuation of HTPN or death

    Number/year and TPN related or not TPN related

  9. Survival

    Time frame: bi-annually up to 10 years, discontinuation of HTPN or death

    Alive, death: causes, TPN-related or not TPN-related

  10. Liver complications

    Time frame: bi-annually up to 10 years, discontinuation of HTPN or death

    Diagnosis, abdominal ultrasound results, liver biopsy results

  11. Metabolic Bone Disease

    Time frame: bi-annually up to 10 years, discontinuation of HTPN or death

    Bone mineral density results, fracture risk and reported fractures

  12. Quality of life based on Karnofsky performance scale

    Time frame: bi-annually up to 10 years, discontinuation of HTPN or death

    Karnofsky performance scale (0-100 point scale)

Study contacts

Contact information is provided by the study sponsor or research team.

Johane Allard, MD,FRCPC

CONTACT

[email protected]

416-340-5159

Katherine JP Schwenger, BASc, MAN, RD, PhD

CONTACT

[email protected]

+1-416-340-4413

Sponsors and collaborators

Lead sponsor

University Health Network, Toronto

Other

Collaborators

  • Baxter Healthcare Corporation
  • Canadian Nutrition Society
  • Ontario Medical Supply

Registry information

Official study title

Home Total Parenteral Nutrition (HTPN) in Canada: A New Website Based Patient Registry

Acronym: HTPN

Important dates

Study start
2005
Primary completion
2029
Study completion
2029
First posted
Nov 24, 2014
Registry last updated
Nov 4, 2022

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.